Sarcopenia is a disease that causes progressive weakness with the loss of muscle mass and quality, and mainly affects people over 60 years of age. The iSARC-GENETICS project, led by Sabartech and Dawako, was created with the aim of becoming the first precision medicine and digital health platform for the early detection of sarcopenia, aiding the diagnosis and monitoring of this disease.
Javier Escobar, chief scientific officer and co-founder of Sabartech, says he aims to “take preventive genetics to another level by incorporating a new multi-scale approach, AI and automation into our research and development”. “Using the revolutionary new Automated Intelligence Genetics (AIG) technology, iSARC-GENETICS will be the first model for the use of this technology,” he says.
The technology to be developed in the project also has other applications, such as in sports medicine and rehabilitation – in order to prevent and treat injuries and obtain the best sports performance -, in obstetrics (remote monitoring and follow-up of pregnancy) and in paediatrics (child nutrition). However, as Sabartech’s scientific director points out, “it is perhaps in the fields of cardiology and oncology, due to its socio-health impact, where this technology could become more relevant in the coming years”.
Supported by
